Search

Your search keyword '"Steg, Ph. Gabriel"' showing total 64 results

Search Constraints

Start Over You searched for: Author "Steg, Ph. Gabriel" Remove constraint Author: "Steg, Ph. Gabriel" Topic cardiovascular diseases Remove constraint Topic: cardiovascular diseases
64 results on '"Steg, Ph. Gabriel"'

Search Results

1. Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES.

2. Omega-3 fatty acids for cardiovascular event lowering.

3. Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.

4. Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial.

5. Do patients benefit from omega-3 fatty acids?

7. Benefits of icosapent ethyl for enhancing residual cardiovascular risk reduction: A review of key findings from REDUCE-IT.

8. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm.

9. Impact of Icosapent Ethyl on Cardiovascular Risk Reduction in Patients With Heart Failure in REDUCE-IT.

11. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.

12. Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.

13. HIV Infection and Long-Term Residual Cardiovascular Risk After Acute Coronary Syndrome.

14. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery.

15. Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk.

16. Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria.

17. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.

18. Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c.

19. Cardiovascular risk in relation to body mass index and use of evidence-based preventive medications in patients with or at risk of atherothrombosis.

20. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial.

21. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry.

22. Outcomes and excess costs among patients with cardiovascular disease.

23. Is it cost-effective to increase aspirin use in outpatient settings for primary or secondary prevention? Simulation data from the REACH Registry Australian Cohort.

24. Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus.

25. Global variation in the prevalence of elevated cholesterol in outpatients with established vascular disease or 3 cardiovascular risk factors according to national indices of economic development and health system performance.

26. Fate of individuals with ischemic amputations in the REACH Registry: three-year cardiovascular and limb-related outcomes.

27. Ethnic differences in cardiovascular risks and mortality in atherothrombotic disease: insights from the Reduction of Atherothrombosis for Continued Health (REACH) registry.

28. Differences in management and outcomes between male and female patients with atherothrombotic disease: results from the REACH Registry in Europe.

29. Statins in the elderly: what evidence of their benefit in prevention?

30. Predictors of annual pharmaceutical costs in Australia for community-based individuals with, or at risk of, cardiovascular disease: analysis of Australian data from the REACH registry.

31. Modifiable risk factors control and its relationship with 1 year outcomes after coronary artery bypass surgery: insights from the REACH registry.

32. One-year cardiovascular event rates in outpatients with atherothrombosis.

33. Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation

34. Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

35. Reduction in Revascularization With Icosapent Ethyl

36. Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses

37. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation

38. Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type

39. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.

40. Predictors of Long‐term Adherence to Evidence‐based Cardiovascular Disease Medications in Outpatients With Stable Atherothrombotic Disease: Findings From the REACH Registry

41. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology

42. The incidence of bradyarrhythmias and clinical bradyarrhythmic events in patients with acute coronary syndromes treated with ticagrelor or clopidogrel in the PLATO (Platelet Inhibition and Patient Outcomes) trial: results of the continuous electrocardiographic assessment substudy

43. Pulse Pressure and Risk for Cardiovascular Events in Patients With Atherothrombosis: From the REACH Registry.

44. Influence of polyvascular disease on cardiovascular event rates. Insights from the REACH Registry.

45. Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial

46. NSAID Use and Association with Cardiovascular Outcomes in Outpatients with Stable Atherothrombotic Disease.

47. Cardiovascular Event Rates in Diabetic and Nondiabetic Individuals With and Without Established Atherothrombosis (from the REduction of Atherothrombosis for Continued Health [REACH] Registry)

48. Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.

49. REDUCE-IT USA: Results From the 3146 Patients Randomized in the United States.

50. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.

Catalog

Books, media, physical & digital resources